In this issue:
A predictive autoantibody for MS
EBV-infected B cells in active MS
CHI3L1 as a biomarker of disease progression in MS
Asymptomatic MRI lesions during attacks & relapse-free periods in NMOSD
Switch from intravenous to subcutaneous natalizumab in MS
Primary care conditions & subsequent risk of MS
Neurologists vs. ChatGPT
EBV & paediatric MS/MOGAD
HIV & risk of MS
Long-term natalizumab vs. interferon beta-1b in SPMS
Please login below to download this issue (PDF)